Mark S Cohen
Chair of the Life Sciences Practice Group
at Pearl Cohen Zedek Latzer Baratz LLP
Mark S Cohen is a founder of Pearl Cohen Zedek Latzer Baratz, LLP; a senior partner; chair of the life sciences practice group; and a member of the firm’s executive committee. His practice focuses on patent prosecution, opinions and commercial transactions in the pharmaceutical, chemical, biological and medical device areas. He is well versed in all aspects of patent prosecution, IP management, strategic advice, technology transfer, commercial transactions and licensing matters. He has been involved in large due diligence matters; infringement, validity and patentability opinions; licensing matters; and commercial transactions. His clients range from start-up companies to Fortune 500 companies.
Mr Cohen was a board member of Masthercell Global Inc, a subsidiary of Orgenesis Inc (Nasdaq: ORGS), a manufacturer, service provider and developer of advanced cell therapies. He was vice chairman of the board and chairman of the governance and nominating committee of Akari Therapeutics, Plc (NASDAQ: AKTX), an emerging biopharmaceutical company that is developing anti-complement and anti-inflammatory molecules as life-transforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases.
He has published in Nature Biotechnology and various patent trade journals. He has lectured at the Practicing Law Institute and the American Conference Institute on general patent topics, and at other venues in the United States on patent issues in the biotechnology/pharmaceutical area. Mr Cohen was named to New York Metro Super Lawyers for 2019 as a top-rated IP lawyer in New York.
Mr Cohen recently represented Orgenesis (NASDAQ: ORGS) in the sale of Masthercell Global, its contract development and manufacturing organisation subsidiary, for $315 million.
He recently represented Ayala Pharmaceuticals in its patent matters and IP commercial matters in its initial public offering, raising gross proceeds of approximately $55 million. Ayala Pharmaceuticals, Inc (NASDAQ: AYLA) is a clinical-stage oncology company focused on developing and commercialising small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.
A deeply strategic thinker with an unwavering focus on the satisfaction of clients’ business objectives, Mark Cohen inspires great confidence. His advice is spot on from substantive legal, technical and commercial perspectives, and is cost-effective too.
- IP management consultancy
- Technology transfer
Pearl Cohen Zedek Latzer Baratz LLP
New York NY 10036